Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

Cantarero, DavidOcaña, DanielOnieva-García, María ÁngelesRodríguez-García, JuanGálvez, PaulinaMéndez, CristinaCrespo Palomo, CarlosLópez-Ibáñez de Aldecoa, Alejandra2025-02-192025-02-192023-08-140264-410Xhttps://hdl.handle.net/2445/218975A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).8 p.application/pdfengcc-by-nc-nd (c) Elsevier B.V., 2023http://creativecommons.org/licenses/by-nc-nd/3.0/es/Vacuna antipneumocòccicaAnàlisi cost-beneficiPneumococcal vaccineCost effectivenessCost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spaininfo:eu-repo/semantics/article7385652025-02-19info:eu-repo/semantics/openAccess